SIGNIFOR LAR 40 MG — DIN 02437260
PASIREOTIDE (PASIREOTIDE PAMOATE) : 40 MG · RECORDATI RARE DISEASES CANADA INC · POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT · wholesale supply in Canada
Health Canada status: MARKETED
What is SIGNIFOR LAR?
SIGNIFOR LAR 40 MG contains PASIREOTIDE (PASIREOTIDE PAMOATE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02437260, held by RECORDATI RARE DISEASES CANADA INC, supplied as POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 21-May-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SIGNIFOR LAR used for?
Treatment of adults with acromegaly (surgery not an option/not curative) or Cushing’s disease (surgery not an option/failed) where clinical benefit or UFC reduction is derived.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Pasireotide cost around the world?
Pasireotide is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Italy publishes a prezzo al pubblico (classe A); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 8 | 8 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 6 | 6 | EUR███.██ |
| South Africa | single exit price | 6 | 6 | ZAR███.██ |
20 pack listings across 20 brand entries and 3 price bases, refreshed 03 Sep 2026. Ranges span every Pasireotide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Pasireotide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Pasireotide — 8 DINs, of which 8 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| RECORDATI RARE DISEASES CANADA INC | 8 | 8 | SIGNIFOR, SIGNIFOR LAR | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 40 MG |
|---|---|
| Dosage form | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | Kits containing one vial of powder, one 2 mL prefilled syringe of diluent, one vial adapter, and one 20G x 1.5” safety injection needle. |
| Storage | Store refrigerated at 2°C to 8°C. Do not freeze. Injection kit must reach room temperature (min 30 mins) before reconstitution. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Pasireotide |
|---|---|
| ATC code | H01CB05 |
| AHFS class | 68:29.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02437260 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2437260 |
| Brand name | SIGNIFOR LAR |
| Generic / active ingredient | PASIREOTIDE (PASIREOTIDE PAMOATE) : 40 MG |
| Market authorization holder | RECORDATI RARE DISEASES CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | H01CB05 |
| ATC anatomical main group | H — Systemic hormonal preparations |
| ATC therapeutic subgroup | H01CB |
| Current status | MARKETED |
| Status date | 21-May-2020 |
| Original market date | 2015-08-04 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Deep IM injection every 4 weeks. Acromegaly: Initial 40 mg, max 60 mg. Cushing’s disease: Initial 10 mg, max 40 mg. Requires 30 min to reach room temperature before reconstitution.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Moderate/severe hepatic impairment; uncontrolled diabetes (HbA1c ≥8%); NYHA Class III-IV heart failure, shock, AV block, sick sinus syndrome, severe bradycardia, LQT syndrome/QTc ≥500 ms; hypersensitivity.
Warnings and precautions
Risk of hepatotoxicity (Hy’s Law reported); cardiovascular events (bradycardia, QT prolongation, AV block); and significant hyperglycemia/diabetes (requires frequent monitoring).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| SIGNIFOR | 0.3 MG | SOLUTION | RECORDATI RARE DISEASES CANADA INC | MARKETED | 02413299 |
| SIGNIFOR | 0.6 MG | SOLUTION | RECORDATI RARE DISEASES CANADA INC | MARKETED | 02413302 |
| SIGNIFOR | 0.9 MG | SOLUTION | RECORDATI RARE DISEASES CANADA INC | MARKETED | 02413310 |
| SIGNIFOR LAR | 20 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | RECORDATI RARE DISEASES CANADA INC | MARKETED | 02437252 |
| SIGNIFOR LAR | 60 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | RECORDATI RARE DISEASES CANADA INC | MARKETED | 02437279 |
| SIGNIFOR LAR | 10 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | RECORDATI RARE DISEASES CANADA INC | MARKETED | 02480425 |
| SIGNIFOR LAR | 30 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | RECORDATI RARE DISEASES CANADA INC | MARKETED | 02480433 |
2 · Same class — other molecules in ATC H01CB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Octreotide | OCPHYL · OCTREOTIDE ACETATE INJECTION · OCTREOTIDE ACETATE INJECTION - 100MCG/ML · OCTREOTIDE ACETATE INJECTION - 200MCG/ML · +7 more | 33 | 9 | Yes |
| Pasireotide | SIGNIFOR · SIGNIFOR LAR | 8 | 8 | Yes |
| Lanreotide | MYTOLAC · SOMATULINE AUTOGEL | 6 | 6 | Yes |
| Somatostatin | STILAMIN - PWS IV 3MG/AMP · STILAMIN - PWS LIQ IV | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC H01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| H01CC | Cetrorelix · Elagolix · Ganirelix · Relugolix, Estradiol And Norethisterone | 6 | 5 |
| H01CA | Gonadorelin · Nafarelin | 4 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.